Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Pedro Rosa‐Neto, Douglas Teixeira Leffa et al.|JAMA Neurology|2022Cited by 261
Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stabilityJoel Simrén, Nicholas J. Ashton, Haley Weninger et al.|Alzheimer s & Dementia|2022Cited by 81
Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individualsWagner S. Brum, Kaj Blennow, Nicholas J. Ashton et al.|Alzheimer s & Dementia|2023Cited by 77
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer DiseasePontus Erickson, Prashanthi Vemuri, Joel Simrén et al.|JAMA Neurology|2023Cited by 46
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individualsJoel Simrén, Kaj Blennow, Wagner S. Brum et al.|Alzheimer s Research & Therapy|2022Cited by 33